Page 1229 - Basic _ Clinical Pharmacology ( PDFDrive )

Index 1215

Growth factor receptor inhibitors, 966t, drug interactions of, 1091 cardiac performance pathophysiology in,
967–969 OTC, 1122t 216f, 216–217
bevacizumab, 966t, 968 pharmacodynamics of, 1089t, 1090, chronic, 221t, 221–224
cetuximab and panitumumab, 966t, 1090f diastolic, 212, 222t, 223
967–968 preparations available, 1117t diuretics for, 227, 270
erlotinib, 966t, 968 prevalence of use of, 1089 nutritional supplements for, 1141
pazopanib, 966t, 969 H 3 -receptor antagonists, 285 pathophysiology of, 215f, 215–216
sorafenib, 966t, 969 H 4 -receptor antagonists, 285 signs and symptoms of, 215
sunitinib, 966t, 969 Haemophilus influenzae type b conjugate systolic, 212, 222t
ziv-aflibercept, 966t, 968 (Hib) vaccine, 1176t treatment of, 217–226, 224t–225t
Growth factors, hematopoietic, 600–605, Hageman defect, 622t ACE inhibitors and ARBs, 222
606t Half-life (t 1/2 ), 45f, 46, 46f beta blockers and ion channel
Growth hormone (GH), 668f, 668–669, on target concentration, 52 blockers, 222
669t, 682t Half-time, context-sensitive, 451, 451f cardiac contractility modulation
chemistry and pharmacokinetics of, 670 Halofantrine, 919f, 920t, 928 therapy, 223
clinical pharmacology of, 671t Halogenated aliphatic hydrocarbons, 1009 cardiac resynchronization, 223
AIDS, 671 Halogens digitalis, 223
anti-aging, 671 chlorine, 899–900 non-inotropic
growth hormone deficiency, 670–671 iodine, 899 ACE inhibitors, 220
short bowel syndrome, 671 iodophors, 899 angiotensin receptor blockers, 220
short-stature pediatric patients, 671 phenolics, 899 beta-adrenoceptor blockers, 221
deficiency of, 667, 670–671, 686 Haloperidol, 160 diuretics, 220
pharmacodynamics of, 670 Huntington’s disease treated with, 505, positive inotropes, 219–221
toxicity and contraindications to, 672 508t beta-adrenoceptor agonists, 219
Growth hormone antagonists, 672–673 psychosis treated with, 515, 515t, 520t, bipyridines, 219
fundamentals of, 672 529t digitalis, 217–219, 218t, 219f, 226t
pegvisomant, 672 structure of, 513f, 515, 515t investigational, 219–220
somatostatin analogs, 672f, 672–673 tics treated with, 506, 508t istaroxime, 219
Growth hormone-releasing hormone Halothane, 441–449. See also Anesthetics, levosimendan, 219
(GHRH), 669, 669t inhaled omecamtiv mecarbil, 219–220
Growth stimulators, 742 properties of, 443t preparations available, 226t
GSK1440115, 318t structure of, 443f sodium removal, 221–222
Guanabenz, 149, 154t, 180. See also Halothane hepatitis, 449 systolic vs. diastolic, 222t
Sympathomimetics Hand-foot syndrome, 958 therapies in, 212–213, 213t
Guanadrel, 181, 191 Hand hygiene, 897 vasodilators, 222
Guanethidine, 181–182, 191t Handle region peptide, 304 Heart rate, 216
Guanfacine, 149, 154t. See also H 1 antihistamines, 1106 Heavy metals, 901, 1020–1029
Sympathomimetics Haplotypes, 75t, 142 arsenic, 1021t, 1025–1027, 1027f
hypertension treated with, 180 Hardy-Weinberg equilibrium, 75t chelators for, 1029–1033, 1033t
tics treated with, 506, 508t Hashimoto’s thyroiditis lead, 1020–1025, 1021t
Guedel’s signs, 446 hypothyroidism from, 689, 696, 696t mercury, 1021t, 1027–1029
Gut microbiota, commensal, 69–70 nontoxic goiter from, 700 poisoning management for, 1045
Gynecologic disorders, androgens and subacute thyroiditis from, 699 Hedeoma pulegeoides extract, 1133t
anabolic steroids for, 742 Hashish. See also Cannabinoids Helminth infections, 938
Gynecomastia, 267 description of, 582 drugs for, 938–947, 939t
G io protein-coupled receptor activation Hematopoiesis, 591–592
H by, 577t, 582–583, 583f Hematopoietic growth factors, 600–605,
H 1 -receptor antagonists, 281–284, 296t Hay fever, 283 606t
chemistry and pharmacokinetics of, 281, Hazard, 1005 clinical uses of, 602t
282f, 283t HDL deficiency, 631 endogenous, 591
clinical pharmacology of, 283–284 Head lice treatment, OTC, 1126t erythropoietin, 601–602, 602t, 606t
pharmacodynamics of, 281–283, 283t Heart block, 234–236, 235f fundamentals of, 600–601
H 2 -receptor antagonists, 284–285, 296t, Heart failure, 212–217 megakaryocyte growth factors, 604–605,
1089–1091. See also specific types acute, 223–224 606t
adverse effects of, 1091 angiotensin-converting enzyme, myeloid growth factors (G-CSF, GM-
chemistry and pharmacokinetics of, 212, 227 CSF), 602t, 602–604, 603f, 606t
1089, 1089t beta-receptor antagonists for, 168 preparations available, 607t
clinical comparisons of, 1089t cardiac contractility control, 213, 214f, Heme carrier protein 1 (HCP1), 593f
clinical uses of, 1090–1091 215 Hemochromatosis, 596